

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 1 (currently amended): A method for ~~screening~~ identifying a compound for an
2 ~~ability to modulate~~ that modulates helicase-dependent p53-mediated apoptosis comprising:

3 (a) providing a biologically active p53 polypeptide, and a helicase
4 polypeptide, wherein the helicase is selected from the group consisting of XPB and XPD,

5 (b) contacting a compound suspected of inducing ~~helicase-~~ dependent p53-
6 mediated apoptosis with the polypeptides of step (a)

7 (c) detecting whether or not the compound is capable of specifically inhibiting
8 binding of the p53 polypeptide to the helicase, wherein a compound that specifically inhibits the
9 binding of the p53 polypeptide to the helicase is a compound that modulates ~~helicase-~~ dependent
10 p53-mediated apoptosis.

2-15 (canceled)

1 16 (previously presented): The method of claim 1, further comprising contacting
2 the polypeptides with a compound that inhibits binding of p53 to XPB or XPD.

1 17 (previously presented): The method of claim 16, wherein the compound that
2 inhibits binding of p53 to XPB or XPD is HBX.

1 18 (currently amended): The method of claim 1, further comprising
2 (d) determining whether the compound suspected of inducing helicase-dependent
3 p53-mediated apoptosis can inhibit helicase activity, wherein a compound that inhibits XPB or
4 XPD helicase activity is a compound that modulates helicase- dependent p53-mediated
5 apoptosis.

1 19 (previously presented): The method of claim 18, wherein the helicase
2 polypeptide is present as part of a TFIIH transcription complex.

1 20 (previously presented): The method of claim 1, wherein the p53 polypeptide
2 and the helicase polypeptide are each introduced into a cell.

1 21 (previously presented): The method of claim 20, wherein at least one of the
2 p53 polypeptide or the helicase polypeptide is a native polypeptide.

1 22 (previously presented): The method of claim 20, wherein the p53 polypeptide
2 is a wild-type p53 polypeptide.

1 23 (previously presented): The method of claim 20, wherein the helicase
2 polypeptide is a mutant helicase polypeptide.

1 24 (previously presented): The method of claim 20, wherein the cell is a member
2 selected from the group consisting of: a fibroblast cell, an epithelial cell, and a hematopoietic
3 cell.